share_log

ALLARITY THERAPEUTICS INC | 8-K: Current report

SEC announcement ·  Mar 26 20:09
Summary by Futu AI
Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company, announced on March 25, 2024, that it has received a formal extension until April 24, 2024, to regain compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1). The extension was granted by the Nasdaq Hearings Panel following the company's strategic plan presentation on February 1, 2024, which outlined immediate and sustained measures to meet compliance requirements. Allarity is working towards achieving a stockholders' equity of at least $2.5 million and a minimum bid price of $1.00 per share for a minimum of 10 consecutive business days. The company's plan includes a comprehensive review and reduction of operating costs, potential conversion of existing liabilities, and pursuit of additional capital. Interim CEO Thomas Jensen expressed confidence in the company's...Show More
Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company, announced on March 25, 2024, that it has received a formal extension until April 24, 2024, to regain compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1). The extension was granted by the Nasdaq Hearings Panel following the company's strategic plan presentation on February 1, 2024, which outlined immediate and sustained measures to meet compliance requirements. Allarity is working towards achieving a stockholders' equity of at least $2.5 million and a minimum bid price of $1.00 per share for a minimum of 10 consecutive business days. The company's plan includes a comprehensive review and reduction of operating costs, potential conversion of existing liabilities, and pursuit of additional capital. Interim CEO Thomas Jensen expressed confidence in the company's ability to execute the plan effectively. The extension does not affect the current trading of Allarity's Common Stock on Nasdaq. Allarity Therapeutics focuses on developing personalized cancer treatments and is currently advancing its novel PARP/Tankyrase inhibitor, stenoparib, in a phase 2 clinical trial for ovarian cancer, using its DRP® companion diagnostic for patient selection.

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.